{
    "clinical_study": {
        "@rank": "58740", 
        "arm_group": {
            "arm_group_label": "thyroid cancer, healty", 
            "description": "Thyroid cancer group: patients with differentiated or dedifferentiated thyroid cancer Healty: control group"
        }, 
        "biospec_descr": {
            "textblock": "Serum"
        }, 
        "biospec_retention": "Samples Without DNA", 
        "brief_summary": {
            "textblock": "In clinical practise patients with negative radioiodine scan with positive tyhroglobulin is\n      considered as radioiodine resistant or in another words in the process of dedifferentiation.\n      The aim of the present study was to search a simple blood test that could lead to early\n      identification of patients with dedifferentiation. In this respect, we investigate whether\n      the serum level of anti-p53 antibody has the diagnostic value in the follow-up of patients\n      with high levels of thyroglobulin (tg) and  negative I-131 scan."
        }, 
        "brief_title": "P53 in Differentiated Thyroid Cancer", 
        "completion_date": {
            "#text": "January 2013", 
            "@type": "Actual"
        }, 
        "condition": "Thyroid Neoplasms", 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Thyroid Neoplasms", 
                "Thyroid Diseases"
            ]
        }, 
        "detailed_description": {
            "textblock": "In the present study enrolled were 171 patients with mean age of 47.7\u00b113.5 yrs (range;\n      16-80yrs) and 28 healthy subjects with an age range of 18-52 yrs (mean: 36.0\u00b19.8 yrs). 134\n      (78.4%) patients were female and 37 (21.6%) patients were male."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients who were diagnosed with DTC\n\n          -  Treated with total and/or near-total thyroidectomy\n\n          -  Referred for I-131 ablation therapy or low dose I-131 whole body scan (WBS)\n\n          -  Between December 2010 and January 2013.\n\n        Exclusion Criteria:\n\n          -  Dose 131-I given in another hospital\n\n          -  Radioiodine treatment more than one year after thyroidectomy."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "16 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "A total of 171 patients with an age range of 16-80 yrs (mean: 47.7\u00b113.5 yrs) and a total\n        of 28 healthy subjects with an age range of 18-52 yrs (mean: 36.0\u00b19.8 yrs) were included\n        in this study."
            }
        }, 
        "enrollment": {
            "#text": "199", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01954134", 
            "org_study_id": "T-485", 
            "secondary_id": "T-485"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Tumor Suppressor Protein p53,", 
            "Iodine Radioisotopes"
        ], 
        "lastchanged_date": "September 26, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Sivas", 
                    "country": "Turkey", 
                    "zip": "58140"
                }, 
                "name": "Cumhuriyet University, School of Medicine, Dept. of Nuclear Medicine"
            }
        }, 
        "location_countries": {
            "country": "Turkey"
        }, 
        "number_of_groups": "1", 
        "official_title": "P53 Antibody; Is it an Indicator of Dedifferentiated Thyroid Cancer?", 
        "overall_official": {
            "affiliation": "Cumhuriyet University", 
            "last_name": "Zekiye Hasbek, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Turkey: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "There was not any risk for patients.", 
            "safety_issue": "Yes", 
            "time_frame": "with in the first 8-10 months after surgery"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01954134"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Cumhuriyet University", 
            "investigator_full_name": "Zekiye HASBEK, M.D., Assistant Professor", 
            "investigator_title": "Cumhuriyet University, School of Medicine, Department of Nuclear Medicine", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "results_reference": [
            {
                "PMID": "19693693", 
                "citation": "Wu M, Mao C, Chen Q, Cu XW, Zhang WS. Serum p53 protein and anti-p53 antibodies are associated with increased cancer risk: a case-control study of 569 patients and 879 healthy controls. Mol Biol Rep. 2010 Jan;37(1):339-43. doi: 10.1007/s11033-009-9744-7. Epub 2009 Aug 20."
            }, 
            {
                "PMID": "16964393", 
                "citation": "M\u00fcller M, Meyer M, Schilling T, Ulsperger E, Lehnert T, Zentgraf H, Stremmel W, Volkmann M, Galle PR. Testing for anti-p53 antibodies increases the diagnostic sensitivity of conventional tumor markers. Int J Oncol. 2006 Oct;29(4):973-80."
            }
        ], 
        "source": "Cumhuriyet University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Cumhuriyet University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2010", 
        "study_design": "Observational Model: Case Control, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "September 2013"
    }
}